PARIS, May 27, 2015 /PRNewswire/ --
Boston Scientific Corporation (NYSE:
BSX) announces the appointment of Professor John Mark Morgan as senior medical director,
Rhythm Management, effective from September
1st, 2015.
Prof. Morgan, an internationally recognised expert clinician in
the field of cardiac rhythm management, will help shape and
influence the advancement of medical therapies across all areas of
the Cardiac Rhythm Management division, with a particular focus on
Europe.
Prof. Morgan currently serves as consultant cardiologist,
specialist in Cardiac Rhythm Management at University Hospital
Southampton NHS Trust, and honorary professor of Cardiac Rhythm
Management at the University of Southampton, United Kingdom. He will leave his
NHS appointment from September
1st but will continue his academic
affiliations.
He has supervised many postdoctoral students, has a research
portfolio of more than 300 publications and has made contributions
to the understanding of cardiac defibrillation, sudden cardiac
death risk stratification and ICD therapy, cardiac
resynchronization therapy, use of implantable technologies for the
management of heart failure, and treatment of complex arrhythmias,
with some particular interest in adult congenital heart disease.
Over the past twenty years he has also served in the leaderships of
national and international societies in a wide variety of roles as
well as advising large corporations in their healthcare technology
development strategies and product development.
"I am very happy about Prof. Morgan joining Boston Scientific.
He will be instrumental in guiding our clinical strategy and
driving innovation in our R&D teams," said Pierre Chauvineau,
vice president Europe, Cardiac
Rhythm Management, Boston Scientific.
"Prof. Morgan is a key addition to our clinical team and we are
looking forward to leveraging his scientific and medical
expertise", added Dr Kenneth Stein,
chief medical officer, Rhythm Management, Boston Scientific.
Prof. Morgan holds a 1st class honours degree in
parts I and II of the Natural Sciences Tripos, graduating from
Gonville and Caius College,
Cambridge. He undertook his
clinical training at Westminster Medical School (now absorbed into
Imperial College) graduating MB BChir in 1982. He became a member
of the Royal College in 1985 and fellow in 1995 and fellow of the
European Society of Cardiology in 2002. He was appointed as
honorary senior lecturer, Southampton Medical School in 1999;
honorary professor at the University of Teesside in 2006; honorary
professor at the School of Medicine, Southampton in 2007; and visiting professor at
Imperial College, London in
2014.
"Boston Scientific has an extensive and innovative rhythm
management portfolio, with technologies that can be truly regarded
as game changers. I am looking forward to starting this new chapter
in my professional life, contributing to further develop the
Company's clinical strategy," said Prof. Morgan.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
solutions that improve the health of patients around the world. As
a global medical technology leader for more than 30 years, we
advance science for life by providing a broad range of high
performance solutions that address unmet patient needs and reduce
the cost of healthcare. For more information, visit
http://www.bostonscientific.eu and connect on Twitter and
Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect,"
"project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials and impact of data,
product performance and impact and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A - Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.